Multilevel white matter degeneration associated cognitive dysfunction in mild cognitive impairment

Yu Chen1, Tiantian Liu2, Li-Zhi Cao1

  • 1School of Medical Technology, Beijing Institute of Technology, Haidian District, Beijing, China.

Molecular Psychiatry
|August 27, 2025
PubMed

Insights

Mild cognitive impairment (MCI) involves white matter (WM) damage impacting cognitive function. This study reveals how WM microstructure changes mediate cognitive decline in prodromal dementia.

Area of Science:

  • Neuroimaging
  • Neuroscience
  • Neurology

Background:

  • Mild cognitive impairment (MCI) is the preclinical stage of dementia, marked by cognitive deficits and white matter (WM) alterations.
  • Understanding WM microstructure changes and their impact on cognition is crucial for early diagnosis and intervention in prodromal dementia.

Purpose of the Study:

  • To investigate WM microstructure degeneration at multiple scales in individuals with MCI.
  • To analyze the mediating role of structural connectome in the relationship between WM alterations and cognitive dysfunction.

Main Methods:

  • Fixel-based analysis (FBA) using fixelwise and fiberwise measures in 50 MCI patients and 75 healthy controls.
  • Structural connectome analysis to examine network-level effects on WM-cognition associations.

Main Results:

  • Patients with MCI showed widespread fiber-specific WM disruptions, including decreased fiber density and cross-section in commissural and association fibers.
  • WM microstructural degeneration was associated with multi-domain cognitive impairments.
  • The structural connectome between visual and salience networks mediated the link between WM damage and impaired language and memory functions.

Conclusions:

  • WM microstructure damage at different scales contributes to cognitive decline in MCI.
  • Network-level interactions, particularly involving visual and salience networks, are critical in mediating the effects of WM alterations on specific cognitive domains.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
165
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
255
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
964
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206